Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent Pneumococcal conjugate vaccine implementation in France

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Janoir, Claire ^a,b   Lepoutre, Agnès ^c   Gutmann, Laurent ^a   Varon, Emmanuelle ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b University Paris Sud   (France)

^c INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

13 valent conjugate vaccine; Antibiotic resistance; Invasive disease; Serotype; Streptococcus pneumoniae

Indexed keywords

CEFOTAXIME; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; TETRACYCLINE;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CHILD; CONTROLLED STUDY; DISK DIFFUSION; GENETIC ANALYSIS; GENOTYPE; HUMAN; INCIDENCE; INFANT; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PHENOTYPE; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 85000605774     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw020     Document Type: Article

References (24)

1. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med 2013; 3:a010215.
2. Reinert RR, Reinert S, van der Linden M, et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European Countries from 2001 to 2003. Antimicrob Agents Chemother 2005; 49:2903-13.
3. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate formulation and use, part I. Clin Infect Dis 2000; 30:100-21.
4. Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 33:359-66.
5. Levy C, Varon E, Picard E, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent conjugate vaccine in France. Pediatr Infect Dis J 2014; 33:1216-21.
6. Grall N, Hurmic O, Al Nakib M, et al. Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 2011; 30:1511-9.
7. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Available at: http://www.eucast. org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_ breakpoints_v_2.0_111130.pdf?bcsi_scan_628cd39dca2568d2=0&bcsi_scan_ filename=EUCAST_breakpoints_v_2.0_111130.pdf. Accessed 15 September 2015.
8. Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014; 58:6484-9.
9. Janoir C, Cohen R, Levy C, et al. Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France. PLoS One 2014; 9:e90935.
10. Santoro F, Vianna ME, Roberts AP. Variation on a theme; an overview of the Tn916/Tn1545 family of mobile genetic elements in the oral and nasopharyngeal streptococci. Front Microbiol 2014; 5:535.
11. Mingoia M, Tili E, Manso E, et al. Heterogeneity of Tn5253-like composite elements in clinical Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2011; 55:1453-9.
12. Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics 2014; 134:210-7.
13. Von Gottberg A, de Gouveia L, Tempia S, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014; 371:1889-99.
14. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-19.
15. ANSM. L'évolution des consommations d'antibiotiques en France entre 2000 et 2013-Novembre 2014. Available at: http://ansm.sante.fr/var/ansm_site/ storage/original/application/28f39921e2a8d8368a1fbfcdc496bd88.pdf. Accessed September 2015.
16. European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe 2012. Available at: http://ecdc.europa.eu/en/publications/ Publications/antimicrobial-consumption-europe-esac-net-2012.pdf. Accessed 15 September 2015.
17. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England andWales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535-43.
18. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301.
19. Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006; 194:682-8.
20. Aguiar SI, Pinto FR, Nunes S, et al. Denmark14-ST230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol 2010; 48:101-8.
21. Hanage WP, Kaijalainen TH, Syrjänen RK, et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect Immun 2005; 73:431-5.
22. Sadowy E, Kuch A, Gniadkowski M, Hryniewicz W. Expansion and evolution of the Streptococcus pneumoniae Spain9V-ST156 clonal complex in Poland. Antimicrob Agents Chemother 2010; 54:1720-7.
23. Rakov AV, Ubukata K, Robinson DA. Population structure of hyperinvasive serotype 12F, clonal complex 218 Streptococcus pneumoniae revealed by multilocus boxB sequence typing. Infect Genet Evol 2011; 11:1929-39.
24. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010; 50:329-37.